Phibro Animal Health Corporation

Phibro Animal Health Corporation

PAHCยทNASDAQ

$31.79

+11%
HealthcareDrug Manufacturers - Specialty & Generic

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.

At a Glance

Live Snapshot
Market Cap$1.29B
EPS1.1900
P/E Ratio26.71
Earnings Date08/26/2026
7.18%
Return on Invested Capital
396%
3Y+2.0%
5Y+111.0%
10Y-61.0%
16.89%
Return on Equity
1695%
3Y-10.0%
5Y-5.0%
10Y-82.0%
3.55%
Return on Assets
1342%
3Y-33.0%
5Y-17.0%
10Y-74.0%
Phibro Animal Health Corporation

Phibro Animal Health Corporation Management Team

PAHC ยท NASDAQ
MR

Mr. Rob Aukerman

Advisor

Compensation

$752,702

Born 1958(Age 68)
male
MJ

Mr. Jack Clifford Bendheim

Chairman, President & Chief Executive Officer

Compensation

$3,962,890

Born 1947(Age 79)
male
MG

Mr. Glenn C. David

Chief Financial Officer

Compensation

$416,796

Born 1972(Age 54)
male
ML

Mr. Larry L. Miller

Chief Operating Officer

Compensation

$2,134,234

Born 1964(Age 62)
male
MD

Mr. Daniel M. Bendheim J.D.

Executive Vice President of Corporate Strategy & Director

Compensation

$763,243

Born 1972(Age 54)
male
MJ

Mr. Jonathan Bendheim

Executive Vice President of Global Technology & People and Director

Born 1977(Age 49)
male
MR

Mr. Ramon Fuenmayor

President South America Region

male
MS

Mr. Samson Li

President of Asia Pacific Region

Born 1972(Age 54)
male
ML

Ms. Lisa A. Escudero

Senior Vice President of Human Resources

Born 1962(Age 64)
female
MJ

Ms. Judith A. Weinstein

Senior Vice President, General Counsel & Corporate Secretary

Born 1969(Age 57)
female
pahc

Phibro Animal Health Corporation Insider Positioning

PAHC ยท NASDAQ

During the last 12 months, insiders have purchased $318K and sold $12.02M worth of PAHC shares, resulting in $11.70M of net selling activity.

3 Months

Bought

10.0K

317.70K

Sold

40.9K

2.17M

Net Activity

-1.8M

-$1.85M

3-6 Months

Bought

0

0.00

Sold

137.1K

6.51M

Net Activity

-6.5M

-$6.51M

6-9 Months

Bought

0

0.00

Sold

76.4K

3.34M

Net Activity

-3.3M

-$3.34M

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

1
CET

Corcoran E Thomas

Director

10.0K sharesโ€ข1 transactions

$318K

Top Sellers

1
BJ

Bendheim Jack

Director, 10 Percent Owner, Officer: President And Ceo

254.4K sharesโ€ข41 transactions

$12.02M

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $11.70M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.03:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Recent Trend (3 Months)

$1.85M

Heavy recent selling activity. Recent insider sales notably exceed purchasesโ€”may warrant investigation into company developments.

Insider Participation

Balanced

1 insider buyers and 1 sellers. Equal participation suggests mixed or neutral insider views.

Insider Activity Insight

Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.

SEC Filings

PAHC - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2025

N/A

September 19, 2025
November 04, 2025
2025
DEF 14A

DEF 14A 2024

N/A

September 20, 2024
November 05, 2024
2024
DEF 14A

DEF 14A 2023

N/A

September 15, 2023
November 06, 2023
2023
DEF 14A

DEF 14A 2022

N/A

September 16, 2022
November 07, 2022
2022
DEF 14A

DEF 14A 2021

N/A

September 17, 2021
November 01, 2021
2021
DEF 14A

DEF 14A 2020

N/A

September 18, 2020
November 02, 2020
2020
DEF 14A

DEF 14A 2019

N/A

September 20, 2019
November 04, 2019
2019
DEF 14A

DEF 14A 2018

N/A

September 21, 2018
November 05, 2018
2018
DEF 14A

DEF 14A 2017

N/A

September 22, 2017
November 06, 2017
2017
DEF 14A

DEF 14A 2016

N/A

September 23, 2016
November 07, 2016
2016
Showing 1 to 10 of 12 filings